NCT06919679View on ClinicalTrials.gov

Phase II Trial of BrECADD in HIV-Positive Patients With Advanced-Stage Classical Hodgkin Lymphoma

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

35

Participants

Timeline

Start Date

August 31, 2025

Primary Completion Date

January 31, 2028

Study Completion Date

January 31, 2030

Conditions

Hodgkin Lymphoma (Category)

Interventions

DRUG

BrECADD

Brentuximab Vedotin Etoposide Cyclophosphamide Doxorubicin Dacarbacine Dexamethasone

All Listed Sponsors

lead

University of Cologne

OTHER